196 related articles for article (PubMed ID: 12727072)
1. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa.
Higgins PG; Fluit AC; Milatovic D; Verhoef J; Schmitz FJ
Int J Antimicrob Agents; 2003 May; 21(5):409-13. PubMed ID: 12727072
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
Jalal S; Wretlind B
Microb Drug Resist; 1998; 4(4):257-61. PubMed ID: 9988043
[TBL] [Abstract][Full Text] [Related]
3. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Jalal S; Ciofu O; Hoiby N; Gotoh N; Wretlind B
Antimicrob Agents Chemother; 2000 Mar; 44(3):710-2. PubMed ID: 10681343
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.
Kugelberg E; Löfmark S; Wretlind B; Andersson DI
J Antimicrob Chemother; 2005 Jan; 55(1):22-30. PubMed ID: 15574475
[TBL] [Abstract][Full Text] [Related]
7. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
Mouneimné H; Robert J; Jarlier V; Cambau E
Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the
Nguyen KV; Nguyen TV; Nguyen HTT; Le DV
Infect Drug Resist; 2018; 11():275-282. PubMed ID: 29535543
[TBL] [Abstract][Full Text] [Related]
9. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
[TBL] [Abstract][Full Text] [Related]
10. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
[TBL] [Abstract][Full Text] [Related]
11. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
13. Gene-Gene Interactions Dictate Ciprofloxacin Resistance in Pseudomonas aeruginosa and Facilitate Prediction of Resistance Phenotype from Genome Sequence Data.
Rehman A; Jeukens J; Levesque RC; Lamont IL
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0269620. PubMed ID: 33875431
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography.
Matsumoto M; Shigemura K; Shirakawa T; Nakano Y; Miyake H; Tanaka K; Kinoshita S; Arakawa S; Kawabata M; Fujisawa M
Int J Antimicrob Agents; 2012 Nov; 40(5):440-4. PubMed ID: 22884856
[TBL] [Abstract][Full Text] [Related]
16. [Mutations of gyrA gene and parC gene in fluoroquinolone-resistant Escherichia coli isolates from sporadic diarrheal cases].
Ishiguro F; Toho M; Yamazaki M; Matsuyuki S; Moriya K; Tanaka D; Isobe J; Kyota Y; Muraoka M
Kansenshogaku Zasshi; 2006 Sep; 80(5):507-12. PubMed ID: 17073264
[TBL] [Abstract][Full Text] [Related]
17. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Akasaka T; Tanaka M; Yamaguchi A; Sato K
Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
Shigemura K; Shirakawa T; Okada H; Hinata N; Acharya B; Kinoshita S; Kofuku T; Kawabata M; Kamidono S; Arakawa S; Gotoh A
Sex Transm Dis; 2004 Mar; 31(3):180-4. PubMed ID: 15076932
[TBL] [Abstract][Full Text] [Related]
19. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the mechanisms of fluoroquinolone resistance in vancomycin-resistant enterococci of different origins.
López M; Tenorio C; Del Campo R; Zarazaga M; Torres C
J Chemother; 2011 Apr; 23(2):87-91. PubMed ID: 21571624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
